256 related articles for article (PubMed ID: 15454951)
1. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
3. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
4. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
5. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
6. A review of gene therapy for haematological disorders.
Nathwani AC; Davidoff AM; Linch DC
Br J Haematol; 2005 Jan; 128(1):3-17. PubMed ID: 15606545
[TBL] [Abstract][Full Text] [Related]
7. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
Sabbioni S; Callegari E; Manservigi M; Argnani R; Corallini A; Negrini M; Manservigi R
Gene Ther; 2007 Mar; 14(5):459-64. PubMed ID: 17051250
[TBL] [Abstract][Full Text] [Related]
8. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
9. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
10. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
11. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
[TBL] [Abstract][Full Text] [Related]
12. Design of retroviral vectors and helper cells for gene therapy.
Hu WS; Pathak VK
Pharmacol Rev; 2000 Dec; 52(4):493-511. PubMed ID: 11121508
[TBL] [Abstract][Full Text] [Related]
13. Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells.
Zhang J; Attar E; Cohen K; Crumpacker C; Scadden D
Gene Ther; 2005 Oct; 12(19):1444-52. PubMed ID: 15877047
[TBL] [Abstract][Full Text] [Related]
14. Retroviral transduction of IL-7Ralpha into IL-7Ralpha-/- bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia.
Jiang Q; Li WQ; Aiello FB; Klarmann KD; Keller JR; Durum SK
Gene Ther; 2005 Dec; 12(24):1761-8. PubMed ID: 16208423
[TBL] [Abstract][Full Text] [Related]
15. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
Ghani K; Cottin S; Kamen A; Caruso M
Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
[TBL] [Abstract][Full Text] [Related]
16. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
17. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks.
Weber E; Anderson WF; Kasahara N
Curr Opin Mol Ther; 2001 Oct; 3(5):439-53. PubMed ID: 11699888
[TBL] [Abstract][Full Text] [Related]
19. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
[TBL] [Abstract][Full Text] [Related]
20. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.
Romano G; Marino IR; Pentimalli F; Adamo V; Giordano A
Drug News Perspect; 2009 May; 22(4):185-96. PubMed ID: 19536363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
